ReviewNature reviews. Rheumatology2024
Recent advances in the diagnosis and management of neuropsychiatric lupus.
Review in Nature reviews. Rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A multidimensional analysis of neuropsychiatric lupus: clinical, biological and imaging insights from systematic evidence.Frontiers in immunology · 2026Pooled it
- From empirical treatment to precision intervention: a multi-database bibliometric analysis of neuropsychiatric systemic lupus erythematosus (2006-2025).Frontiers in immunology · 2026Pooled it
- Diagnosing autoimmune encephalitis in psychiatry: clinical recommendations and unresolved challenges from the GENERATE network.Molecular psychiatry · 2026Review
- Diagnostic value of cerebrospinal fluid antisuprabasin antibody in neuropsychiatric systemic lupus erythematosus.Lupus science & medicine · 2026Article
- Long-term clinical outcomes and safety of rituximab in refractory neuropsychiatric systemic lupus erythematosus: a real-world single-center study.Clinical rheumatology · 2026Article
- Mania and psychosis following chimeric antigen receptor T-cell therapy: A report of two cases and mechanistic discussion.Brain, behavior, & immunity - health · 2026Article
- Automatic choroid plexus assessment in SLE: a deep learning-enabled study.Neuroradiology · 2026Article
- Neurodevelopmental comorbidities in juvenile systemic autoimmune and autoinflammatory diseases.Nature reviews. Rheumatology · 2026Review
- A novel mitochondrial-associated risk score reveals a potential link between pancreatic ductal adenocarcinoma and chemotherapy resistance as well as poor response to immunotherapy.Discover oncology · 2026Article
- Neuropsychiatric systemic lupus erythematosus subtypes identified by unsupervised clustering: A single-center cohort study.Rheumatology and immunology research · 2026Article
- Functional Brain Activity Associated With Intermittent Rhythmic Delta/Theta Activity: A Transdiagnostic Electroencephalography-Functional Magnetic Resonance Imaging Resting-State Study.Biological psychiatry global open science · 2026Article
- Intrathecal injection of rituximab inhibits microglial M1 polarisation to alleviate neuropsychiatric SLE symptoms via the cAMP/PKA/CREB signalling pathway.Lupus science & medicine · 2026Article
- Stem cell-derived extracellular vesicles as immunomodulatory agents: targeting pathological crosstalk in systemic lupus erythematosus and multiple sclerosis.Frontiers in medicine · 2026Review
- Case Report: A rare motor storm in lupus: opsoclonus-myoclonus-ataxia syndrome as an atypical presentation of severe systemic lupus erythematosus.Frontiers in medicine · 2026Article
- Mapping organ-associated autoantigenic landscapes in systemic lupus erythematosus.Frontiers in immunology · 2026Review
- Mendelian Randomization Uncovers Potential Repurposable Medications for Neuropsychiatric Disorders.Current neuropharmacology · 2026Article
- IFNγ-associated immune-metabolic remodeling is linked to serotonin-kynurenine imbalance and cortical vulnerability in lupus-prone mice.Frontiers in immunology · 2026Article
- Comparison of obinutuzumab and rituximab for treating neuropsychiatric lupus: a retrospective case-control study.Lupus science & medicine · 2025Article
- Alterations in functional connectivity analyzed using MREG in patients with suspected autoimmune psychosis spectrum syndromes.Brain, behavior, & immunity - health · 2025Article
- Clinical characteristics and treatment response of patients with SLE complicated with thrombotic thrombocytopenic purpura.Lupus science & medicine · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropsychiatric manifestations of systemic lupus erythematosus (SLE) are common and frequently associated with a substantial negative impact on health outcomes. The pathogenesis of neuropsychiatric SLE (NPSLE) remains largely unknown, but a single pathogenic mechanism is unlikely to be responsible for the heterogeneous array of clinical manifestations, and a combination of inflammatory and ischaemic mechanistic pathways have been implicated. Currently, valid and reliable biomarkers for the diagnosis of NPSLE are lacking, and differentiating NPSLE from nervous system dysfunction not caused by SLE remains a major challenge for clinicians. However, correct attribution is essential to ensure timely institution of appropriate treatment. In the absence of randomized clinical trials on NPSLE, current treatment strategies are derived from clinical experience with different therapeutic modalities and their efficacy in the management of other manifestations of SLE or of neuropsychiatric disease in non-SLE populations. This Review describes recent advances in the understanding of NPSLE that can inform diagnosis and management, as well as unanswered questions that necessitate further research.
Indexed as
Identifiers
39358609What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.